Pfizer's Q1 2026 Earnings: Vyndamax Patent Win, Pipeline Focus

0:00Pfizer's gearing up for its first quarter of 2026 earnings report this Tuesday, May 5th, before the market opens, followed by an analyst. Call at 10 a.m. Eastern Daylight Time. Goldman Sachs just dialed back its price target to $26, signaling they want solid proof that Pfizer's post-COVID business can hold. Stetty on revenue, tight-cost controls, and a promising drug pipeline. The company already laid out its full-year 2026 guidance, projecting revenue between $59.5 billion and $62.5 billion with adjusted earnings per share from $2.80 to $3. That factors in a $1.5 billion drop from COVID products compared to last year plus another $1.5 billion hit from drugs. Losing patent protection. Wall Street's staying on the sidelines because Pfizer's still wrestling with replacing Blockbuster revenue lost to generics, even as it pumps out. Strong cash flow from its global ups. Meanwhile,

1:01they're budgeting $12.5 to $13.5 billion for sales and admin costs, and $10.5 to $11.5 billion for research and development. A bright spot hit just before earnings. Pfizer's settled patent fights with generic makers like Dixiel, Hickman, and Cipla over its hard-drug Vindamax, pushing off U.S. competition until June 1, 2031. That drug pulled in nearly $6.4 billion last year, and now sales should stay steady through mid-2031 instead of tanking. Early. With the pipeline front and center, Pfizer's zeroing in on key therapies like a new buy-specific antibody and programs from recent deals, but investors might need real growth winds beyond cost savings and this Vindamax breather to shift the stock higher.